logo
Share SHARE
FONT-SIZE Plus   Neg

Genentech Says SUMMACTA Study Meets Primary Endpoint - Quick Facts

Genentech, a member of the Roche Group (RHHBY.PK), announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous formulation every four weeks.

A similar proportion of rheumatoid arthritis patients in each group achieved an ACR20 response at Week 24, a measure indicating improvement in the number of tender and swollen joints, pain scale, patients' and physicians' assessment of improvement and certain laboratory markers.

Hal Barron, chief medical officer and head, Global Product Development, stated, "We are very pleased with these data showing that subcutaneous administration of ACTEMRA provides clinically meaningful and comparable results to the IV infusion. This may provide patients and their doctors with an important additional treatment option."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
France-based optical-lens maker Essilor International SA (EL), Delfin and Ray-Ban maker Luxottica Group (LUX) Monday announced their plan to merge in a deal valued around $49 billion. Essilor would become a holding company with the new name "EssilorLuxottic." Uncertainty has become the name of the game, as the new president is set to assume office. Groundwork is being done for major policy overhauls, with the first step towards repealing the Obamacare taken, as Senators voted 51-48 to approve a budget resolution for achieving the same. The House is set to... A country's productivity is measured by dividing its gross domestic product or GDP in U.S. dollars and normalized to purchasing power parities by the total number of hours worked by the country's workforce in a year. It is considered as a key driver of long-term economic growth and living standards. CLICK...
comments powered by Disqus
Follow RTT